醫療事業 | 文教事業 | 生技事業 | 公益事業 | 管理事業 | 中國事業


 

 繁體版 / 簡體版/ 回諾貝爾集團首頁

 
   
 
   

諾貝爾集團 > 諾貝爾醫療事業 > 諾貝爾眼科雷射機構 > 雷射論壇 > 法國巴黎2004年歐洲眼科醫學會報告

回首頁

美麗爾醫學美容機構

最新消息

環境介紹

醫療團隊

門診時間

線上掛號

診療項目

眼科小百科專欄

眼科疾病的治療與保健

談眼科疾病及雷射手術

雷射屈光性手術學

眼病學

眼科雷射近視專欄

眼科雷射經驗分享

張醫師國際會議實錄

媒體報導

電子媒體

    電視
    廣播
平面媒體
    報紙
    雜誌

停車資訊

聯絡我們

法國巴黎2004年歐洲眼科醫學會報告
Therapeutic Treatment of Irregular Astigmatism and CentralIsland
with Wavefront-Driven Ablations

▲ 回雷射近視手術專論─專業論文清單

張朝凱

諾貝爾眼科

Purpose: To demonstrate the use of wavefront-guided ablations to treat post-LASIK re-treatments for patients with irregular astigmatism and central island.

Methods: 10 patients underwent therapeutic ablations to treat post-LASIK visual complications.5 patients presented with different etiologies of irregular astigmatism including de-centration.The other 5 patients presented with central island.The PreVue lens was used for all 10 patients and the WaveScan data was used to re-treat the eyes with the VISX STAR S4 laser.

Results: Patients were followed for one year following re-treatment and 80% of eyes (n=8) improved to 20/20 UCVA.2 eyes showed no immediate post-op marked improvement, but at 1 year one has demonstrated some objective improvement.Of the 8 improved eyes 2 have some regression.Pre- and post-operative initial LASIK data, pre-and post-op re-treatment data including UCVA, BCVA, topography and wavefront maps will all be reviewed.Contrast sensitivity and changes in intra-ocular pressure will also be reviewed.

Conclusion: The VISX CustomVue system can be used safely and effectively to perform therapeutic re-treatments on patients with post-LASIK irregular astigmatism and central island.